home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2629.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
36 lines
Document 2629
DOCN M94A2629
TI Macrophages' function in the treatment of HIV 1 infected children.
DT 9412
AU Sizyakina LP; Chernyshov VN; Simovanian EN; Shemshura AB; Denisenko VB;
Medical Institute, Rostov-on-Don, Russia.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):260 (abstract no. PB0469). Unique
Identifier : AIDSLINE ICA10/94369946
AB A total of 53 children aged 3-10 years having the diagnosis of HIV-1
infection were examined. 33 patients (14--at the stage of primary
symptoms, 19--at the stage of secondary diseases) were given retrovir
180 mg/m2, 4 times per day. The rest 20 patients (7-at the stage of
primary symptoms, 13--at the stage of secondary diseases) were not given
retrovir. It was established that retrovir was more effective at the
early stage of HIV-1 infection. The application of retrovir at the stage
of primary symptoms leads to the reducing of the increasea expression of
FcR and C3bR in monocytes, to the slight diminution of their absorbing
ability and intensity of oxygendependent metabolism alongside with the
simultaneous increase of the reserved potentials, digesting activity and
secretion of IL-1. The application of retrovir at the stage of secondary
diseases allows to preserve considerable reserved potentiaes of
macrophages, their ability to synthesize IL-1, but at the same time it
causes the following suppression of C3bR expression and the marked
supression of phagocytosis. In all patients gene pol expression was
detected.
DE Child Child, Preschool Female Human HIV Infections/*DRUG
THERAPY/IMMUNOLOGY HIV-1/*DRUG EFFECTS/IMMUNOLOGY
Interleukin-1/BIOSYNTHESIS Macrophage Activation/DRUG
EFFECTS/IMMUNOLOGY Macrophages/*DRUG EFFECTS/IMMUNOLOGY Male
Phagocytosis/DRUG EFFECTS/IMMUNOLOGY Zidovudine/*ADMINISTRATION &
DOSAGE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).